TransMedics Group, Inc. $TMDX Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Key Points

• UBS Asset Management cut its TransMedics position by 57.6% in the second quarter, selling 541,273 shares and retaining 398,250 shares worth approximately $26.5 million. Institutional investors collectively own 99.67% of the company.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 fell short of the $0.50 consensus forecast.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $124.18, compared with the stock’s reported price of $86.98.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 57.6% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 398,250 shares of the company's stock after selling 541,273 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.15% of TransMedics Group worth $26,452,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Harvest Fund Management Co. Ltd purchased a new stake in TransMedics Group during the 3rd quarter worth $29,000. Allworth Financial LP increased its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company's stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company's stock valued at $34,000 after buying an additional 83 shares during the period. Ascentis Independent Advisors bought a new stake in shares of TransMedics Group during the 1st quarter valued at about $30,000. Finally, North Star Investment Management Corp. bought a new stake in shares of TransMedics Group during the 1st quarter valued at about $30,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Price Performance

NASDAQ TMDX opened at $86.98 on Friday. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The firm has a market capitalization of $3.01 billion, a PE ratio of 22.36 and a beta of 1.90. The company's 50 day simple moving average is $79.71 and its 200 day simple moving average is $92.23. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business's revenue for the quarter was up 20.7% on a year-over-year basis. During the same quarter last year, the company earned $0.92 earnings per share. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on TMDX shares. Stifel Nicolaus boosted their price objective on TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research report on Thursday, June 18th. UBS Group cut their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 5th. Wall Street Zen downgraded shares of TransMedics Group from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $124.00 price objective on shares of TransMedics Group in a report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $124.18.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source